Physician profile
Michael Ditkowsky
NPI 1629079546
$4,362.26
in general payments reported to CMS, 2019-2025
21 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $55.85 · 2021: $173 · 2022: $254 · 2023: $678 · 2024: $1,566 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,498.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $611.61 | 2024-2025 | Miebo, Xiidra, Vyzulta |
| Alexion Pharmaceuticals, INC. | $475.07 | 2023-2025 | Ultomiris, Soliris |
| Glaukos Corporation | $461.01 | 2019-2025 | Photrexa |
| Tarsus Pharmaceuticals, INC. | $344.28 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $332.23 | 2023-2025 | Cequa |
| Biotissue Holdings INC. | $294.88 | 2022-2024 | |
| Dompe US, INC. | $247.18 | 2024-2025 | Oxervate |
| Alcon Vision LLC | $222.63 | 2023-2025 | Total30, Precision 1, Dailies Total1 |
| Amgen INC. | $205.80 | 2024-2025 | Tepezza |
| Coopervision INC. | $189.87 | 2019-2023 | Myday Contact Lens |
| Rxsight INC | $146.76 | 2024 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Genzyme Corporation | $133.03 | 2020-2022 | |
| Oyster Point Pharma, INC. | $117.76 | 2023 | Tyrvaya |
| Visioneering Technologies, INC. | $96.11 | 2019 | |
| Harrow Eye, LLC | $81.58 | 2025 | Vevye |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $77.18 | 2022 | |
| Horizon Therapeutics Plc | $77.17 | 2023 | Tepezza |
| Aerie Pharmaceuticals, INC. | $73.32 | 2019 | |
| Kala Pharmaceuticals, INC. | $66.37 | 2021 | |
| Maculogix, INC. | $58.26 | 2019 | |
| Allergan, INC. | $50.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ditkowsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.